ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2089

Downregulation Of Mir-10a Is Associated With Increased Von Willebrand Factor Antigen, Disease Activity Score and Earlier Diagnosis In Children With Untreated Juvenile Dermatomyositis

Dong Xu1,2, Akadia Kachaochana1, Gabrielle A. Morgan3, Chiang-Ching Huang4 and Lauren M. Pachman2,3, 1Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 2Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, 4Zilber School of Public Health, University of Wisconsin at Milwaukee, Milwaukee, WI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Inflammation, musculoskeletal disorders and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: We previously reported (Arthritis Rheum 2012;64 Suppl 10:1670) that miRNA array studies of diagnostic muscle biopsies obtained from untreated children with Juvenile Dermatomyositis (JDM) identified 19 differentially expressed miRNAs in JDM muscle compared to healthy orthopedic controls.  Downregulation of miR-10a and miR-10b headed the list with fold changes of -1.96, adjusted p=0.0028, and fold change of -1.62, adjusted p value= 0.0027, respectively. miR-10a and miR-10b are located on separate chromosomes (2 and 17) and regulate the NFκB pathway which controls the synthesis of inflammatory mediators.  We confirmed that plasma levels of IL- 6, IL-8, TNF-α, MCP-1, VCAM-1, but not IL-1β, were elevated in untreated JDM compared to controls.  The purpose of the present study was to determine association of the miR-10a and miR-10b downregulation in the muscle with customary clinical and laboratory findings in untreated children with JDM.

Methods: After obtaining informed consent, 24 children: 11 with a short duration of untreated disease (DUD) of less than 3 months and 13 with a long DUD of greater than 3 months were enrolled; 17 were girls. Of the 24, 19 were White and 5 were Hispanic.  The children were enrolled at the time of diagnosis and their clinical and diagnostic laboratory data examined in relation to the expression levels (qPCR) of miR-10a and miR-10b in the diagnostic muscle biopsy. The clinical variables considered were disease activity scores (DAS, skin, muscle, total score), nailfold capillary end row loop number (ERL) and the blood level of von Willebrand factor antigen (vWF:Ag), DUD, and the presence of the TNF-α-308 A allele.  Healthy orthopedic patients donated muscle from the trunk or proximal limbs as controls.

 Results: Of note, decreased miR-10a, but not miR-10b, was associated with: a short DUD of less than 3 months, p=0.014; the presence of the A allele at the promoter region of TNF-α-308, p=0.006; an elevated DAS Total, p=0.03; and increased vWF:Ag level,  p=0.004.  There was no association of either decreased miR-10a or miR-10b with loss of ERL.

Conclusion: Downregulation of miR-10a, but not miR-10b, was associated with increased vWF:Ag, indicating damaged endothelial cells, and a more severe disease onset with a higher DAS, contributing to earlier diagnosis and a shorter DUD.  We conclude that miR-10a downregulation is a critical factor in JDM pathophysiology and speculate that it may be a potential therapeutic target early in the disease course.


Disclosure:

D. Xu,
None;

A. Kachaochana,
None;

G. A. Morgan,
None;

C. C. Huang,
None;

L. M. Pachman,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/downregulation-of-mir-10a-is-associated-with-increased-von-willebrand-factor-antigen-disease-activity-score-and-earlier-diagnosis-in-children-with-untreated-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology